Financial Archives | Page 43 of 123 | Be Korea-savvy

Archive by category Financial

Spend Matters Secures Investment from Copley Equity Partners

Spend Matters Secures Investment from Copley Equity Partners

BOSTON, Dec. 9 (Korea Bizwire) – Copley Equity Partners, LLC (“Copley”), a private investment firm focused on lower middle-market companies with strong growth opportunities, today announced that it has made an investment in Spend Matters, a proprietary tech-enabled data platform that drives and optimizes the strategic technology procurement decisions across the global procurement, finance, and supply chain [...]

Imperial Capital Opens Authorized European Company in Milan, Italy to Conduct European Business and Names Julien Sida as its CEO

Imperial Capital Opens Authorized European Company in Milan, Italy to Conduct European Business and Names Julien Sida as its CEO

LOS ANGELES, Dec. 9 (Korea Bizwire) — Imperial Capital Group, LLC (“Imperial Capital”) announced that its affiliate, Imperial Capital (International) LLP (“Imperial Capital International”), has completed the process of transitioning its Milan Branch into an authorized subsidiary amidst the end of the Brexit transition period whereby passporting between the UK and EEA states ceased. The [...]

Nasdaq Survey Uncovers Portfolio Managers’ Top Data Infrastructure Challenges

Nasdaq Survey Uncovers Portfolio Managers’ Top Data Infrastructure Challenges

NEW YORK, Dec. 6 (Korea Bizwire) — Nasdaq, Inc. (Nasdaq: NDAQ) today released results from a survey of portfolio managers across the U.S., revealing the top challenges they face in operating a scalable and efficient data infrastructure. Only 46% of respondents report being very or completely satisfied with their organization’s data infrastructure, and only 2% [...]

Capitalworks Emerging Markets Acquisition Corp Announces Closing of $230 Million Initial Public Offering, Including Full Exercise of the Underwriters’ Over-Allotment Option

Capitalworks Emerging Markets Acquisition Corp Announces Closing of $230 Million Initial Public Offering, Including Full Exercise of the Underwriters’ Over-Allotment Option

NEW YORK, Dec. 3 (Korea Bizwire) — Capitalworks Emerging Markets Acquisition Corp (the “Company”), a special purpose acquisition company, today announced the closing of its initial public offering of 23,000,000 units at a price of $10.00 per unit, which includes the full exercise of the underwriters’ option to purchase an additional 3,000,000 units from the [...]

Institutional Investor Publishes 2021 Global Fixed-Income Research Rankings

Institutional Investor Publishes 2021 Global Fixed-Income Research Rankings

NEW YORK, Dec. 1 (Korea Bizwire) — In 2021 Institutional Investor’s Global Fixed-Income Research survey, 6,025 bond and credit specialists from 1,622 asset managers provided their feedback to determine the top fixed-income research providers for developed and emerging markets across North America, Latin America, Asia-Pacific, Europe and Emerging EMEA. Voters cast over 126,000 firm and [...]

Capitalworks Emerging Markets Acquisition Corp Announces Pricing of $200 Million Initial Public Offering

Capitalworks Emerging Markets Acquisition Corp Announces Pricing of $200 Million Initial Public Offering

NEW YORK, Nov. 30 (Korea Bizwire) — Capitalworks Emerging Markets Acquisition Corp (the “Company”), a special purpose acquisition company, today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. The units will be listed on The Nasdaq Global Market (“Nasdaq”) and will begin trading on December [...]

Jeito Capital Co-leads $156 Million Oversubscribed Series B financing in Quell Therapeutics

Jeito Capital Co-leads $156 Million Oversubscribed Series B financing in Quell Therapeutics

Paris, France, Nov. 29 (Korea Bizwire) – Jeito Capital (“Jeito”), a leading independent private equity firm dedicated to biotech and biopharma, today announces that it has co-led a $156 million oversubscribed Series B financing round in Quell Therapeutics (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by [...]